# Gate v2 answers for clinical review

Source: `docs/eval/run8_arm_a_merge_external_20260725_233343.json` (Run 8, arm A, after the retry-merge fix).

**Predates** the later retrieval fixes (terms-only citation query, branch scope-lock, dual-source anchor). Graded by an external GPT-5 judge.


---

## batch_f2_clti_itp_after_bypass — turn 1 — **PASS_WITH_MINOR**

**Evidence coverage:** `interaction_gap`  |  **Routed:** clti, antithrombotic_therapy


### Answer as delivered

## ESVS-grounded answer

The ESVS guidelines recommend single antiplatelet therapy as standard after vein bypass for CLTI, and support antiplatelet therapy after prosthetic grafts to maintain patency. Warfarin may be considered for high-risk vein grafts (e.g., spliced vein, poor runoff) only if bleeding risk is not increased. There is no ESVS recommendation on how to modify antithrombotic therapy in the presence of significant bleeding risk, such as from immune thrombocytopenic purpura (ITP).

## Interpretation

Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
In the absence of guideline coverage for CLTI patients with ITP, the choice and safety of antithrombotic therapy must be individualized, taking into account the severity of thrombocytopenia and the graft type. In patients with severe thrombocytopenia, antiplatelet or anticoagulant therapy may pose significant bleeding risks, potentially overriding standard recommendations for graft patency. Multidisciplinary input (haematology and vascular surgery) is advised to balance thrombosis and bleeding risk. If platelet count is very low, withholding antithrombotics—even temporarily—may be justified, while maintaining close surveillance for graft patency and ischemic complications.


### External judge

**Grade:** PASS_WITH_MINOR

**Labels:** F2

**Reason:** The answer correctly identifies the post-operative CLTI context with ITP after bypass, acknowledges that ITP may move the patient outside standard recommendations, emphasizes individualized management based on platelet count/bleeding risk, and allows for temporary withholding/stepwise escalation. It asks appropriate high-yield questions within the limit. However, it omits the core element that standard therapy includes aspirin plus low-dose rivaroxaban when bleeding risk is acceptable.


---

## batch_s2_post_vein_bypass_antithrombotics — turn 1 — **FAIL**

**Evidence coverage:** `interaction_gap`  |  **Routed:** clti, antithrombotic_therapy


### Answer as delivered

## ESVS-grounded answer

From the retrieved ESVS snippets: 1) The BOA RCT showed that oral anticoagulation with a VKA (INR target reported in the trial 3.0–4.5) improved bypass patency for patients with vein grafts compared with aspirin, whereas aspirin performed better for prosthetic grafts. 2) For endovascular lower limb interventions, Recommendation 36 suggests considering aspirin (75–100 mg once daily) combined with low-dose rivaroxaban (2.5 mg twice daily) in patients not at high bleeding risk. 3) Recommendation 43 notes that patients at high bleeding risk undergoing infrainguinal bypass may be considered for single antiplatelet therapy to improve graft patency. 4) The guidance also states not to add clopidogrel to aspirin plus rivaroxaban for more than 30 days and only in exceptional circumstances. No explicit, consolidated ESVS recommendation specific to a below‑knee autologous vein bypass in a patient with CLTI/rest pain and low bleeding risk (i.e. directly comparing VKA versus antiplatelet ± low‑dose rivaroxaban for this scenario) was found in the provided snippets.

## Interpretation

Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
Practical interpretation for a vein below‑knee bypass in a patient with CLTI (rest pain) and low bleeding risk: 1) The BOA trial evidence supports that therapeutic oral anticoagulation (VKA, as studied) can improve patency of autologous vein grafts versus aspirin, but this must be balanced against increased bleeding risk. 2) The aspirin plus low‑dose rivaroxaban combination has trial‑based recommendations for post‑endovascular procedures to reduce cardiovascular and limb events, but the retrieved guideline excerpts do not provide a direct recommendation to substitute that regimen for surgical vein bypass. 3) In practice, choice between VKA anticoagulation and antiplatelet-based strategies after infrainguinal vein bypass depends on graft type (autologous vein favours consideration of anticoagulation per BOA), patient bleeding risk, and centre/local practice. 4) Discuss options with the patient and multidisciplinary team (vascular surgery, anticoagulation clinic), document rationale, and plan surveillance for graft patency and bleeding. If you want a specific regimen recommendation for this exact scenario (vein BK bypass, CLTI, low bleeding risk), further guideline text or consensus statements addressing the direct comparison for surgical vein bypass are needed to reduce the current interaction gap.


### External judge

**Grade:** FAIL

**Labels:** F1, F3

**Reason:** Does not provide the expected consolidated recommendation for infrainguinal vein below-knee bypass with low bleeding risk (aspirin 75–100 mg daily plus rivaroxaban 2.5 mg BID). Instead, it emphasizes uncertainty, frames the aspirin+rivaroxaban regimen as endovascular-only, and introduces VKA as an option, creating ambiguity. While it notes avoiding prolonged clopidogrel and mentions single antiplatelet therapy for high bleeding risk, the core recommended regimen is missing and the messaging is contradictory to the rubric.


---

## batch_s6_urgent_cea_af_apixaban — turn 1 — **PASS_WITH_MINOR**

**Evidence coverage:** `interaction_gap`  |  **Routed:** carotid_vertebral, antithrombotic_therapy


### Answer as delivered

## ESVS-grounded answer

ESVS guidelines specifically recommend antiplatelet therapy before, during, and after carotid endarterectomy in all recently symptomatic carotid stenosis patients. Dual antiplatelet therapy may be considered after exclusion of intracranial hemorrhage, but this is a class IIa, level C recommendation, and lacks specific trial evidence in the setting of CEA. The guidelines also recommend a multidisciplinary approach for patients with AF and symptomatic carotid stenosis to decide between urgent revascularization and anticoagulation alone. There is no ESVS statement on managing perioperative DOACs (such as apixaban) or on routinely combining anticoagulants with perioperative antiplatelets in this specific context.

## Interpretation

Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
Because there is no direct ESVS guidance on how to manage perioperative apixaban (whether to stop, bridge, or continue) for urgent CEA, and no recommendation for or against the combination of apixaban with periprocedural antiplatelet therapy in this setting, multidisciplinary discussion (vascular, neurology/stroke, anesthesia, hematology) is warranted. Individualized risk assessment (ischemic vs. bleeding risk) is essential. If the decision is to stop apixaban preoperatively, timing must be balanced against the urgency of CEA and stroke risk; local perioperative anticoagulation protocols should be consulted. Many centers would temporarily discontinue the DOAC before CEA (timing based on renal function) and resume only once hemostasis is secure. Whether to add antiplatelet therapy during the perioperative period in a patient already anticoagulated is less clear and should also be addressed multidisciplinary, considering the strong ESVS recommendation for antiplatelets but the known additive bleeding risk with combination therapy.


### External judge

**Grade:** PASS_WITH_MINOR

**Labels:** F2, F7

**Reason:** Covers antiplatelet use and acknowledges perioperative DOAC uncertainty, but does not clearly state that CEA remains urgent, does not explicitly recommend stopping the DOAC without routine bridging, and does not clearly advise avoiding prolonged combination strategies. Leans on multidisciplinary discussion and practice variability without delivering the core, direct recommendations.
